FIELD: pharmaceuticals.
SUBSTANCE: invention relates to new pyrazine compounds of Formula I, where A, B, R1, R2, V, W, X, Y, m, n are defined in the claims and act specifically on adenosine receptors, in particular on A2a. The invention also relates to pharmaceutical compositions containing one or more compounds as an active ingredient, and the use of these compounds in the treatment of diseases associated with adenosine receptors (AR), for example cancer, such as non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), prostate cancer and breast cancer.
EFFECT: obtaining pyrazine compounds and their use.
47 cl, 4 tbl, 308 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
| COMPOUND 8-FLUOROPHTHALAZINE-1(2H)-ONE AS INHIBITORS OF BRUTON TYROSINE KINASE | 2012 |
|
RU2622391C2 |
| SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK, THEIR PREPARATION AND USE IN TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASES | 2014 |
|
RU2677884C2 |
| PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
| SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2781639C2 |
| IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| ANALOGUES OF 4H-PYRAZOLO[1,5-A]BENZIMIDAZOLE COMPOUNDS AS PARP INHIBITORS | 2015 |
|
RU2672722C2 |
